Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Relief Therapeutics (Group)

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100TM is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. *

 

Period Start 2016-06-01 merged
Products Industry drug development
  Industry 2 aviptadil (NN)
Persons Person Selvaraju, Raghuram (Ram) (Relief Therapeutics 202010 Board Chairman)
  Person 2 Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group)
     
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 15 Avenue de Sécheron
Fondation EIP, Bâtiment F2/F3
  City 1202 Genève GE
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency CHF
  Profit -7,828,000 (2020-12-31)
  Cash 35,000,000 (2021-04-15)
     
    * Document for �About Section�: Relief Therapeutics Holding AG. (1/20/21). "Press Release: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil". Geneva & Gundelfingen.
     
   
Record changed: 2021-04-24

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Relief Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px




» top